Last update 29 May 2025

Azelastine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone, Afluon, Allergodil
+ [29]
Action
antagonists, stabilizers
Mechanism
H1 receptor antagonists(Histamine H1 receptor antagonists), Mast cells stabilizers
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (30 Apr 1986),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H25Cl2N3O
InChIKeyYEJAJYAHJQIWNU-UHFFFAOYSA-N
CAS Registry79307-93-0

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Respiratory Tract Infections
United States
17 Jun 2021
Rhinitis, Allergic, Perennial
Australia
21 Jul 2004
Conjunctivitis, Allergic
United States
22 May 2000
Rhinitis, Allergic, Seasonal
United States
01 Nov 1996
Rhinitis, Vasomotor
United States
01 Nov 1996
Dermatitis
Japan
30 Aug 1990
Eczema
Japan
30 Aug 1990
Prurigo
Japan
30 Aug 1990
Pruritus
Japan
30 Aug 1990
Urticaria
Japan
30 Aug 1990
Asthma
Japan
30 Apr 1986
Rhinitis, Allergic
Japan
30 Apr 1986
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rhinitis perennialPhase 3
United States
01 Jan 2007
Chronic rhinitisPhase 3
United States
01 Jul 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
110
Azelastine HCl 0.15% nasal spray
gcgojfjoyk(pxgvgavfwd) = cndydqyrpk sjztizrzes (ahaustghvv )
Positive
01 Jul 2024
Not Applicable
87
Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily)
ozpghaceun(oqgdcinosl): mean difference = 1.26 (95% CI, 0.59 - 1.93), P-Value = <0.001
Positive
23 Feb 2024
Fluticasone furoate (FF 55 μg each nostril once daily)
Phase 3
900
jxmuqygjun(mtbebvvvxd): P-Value = 0.0007
-
01 Sep 2023
Fluticasone propionate nasal spray
Phase 3
581
cgnudtmtrx(nzlxlfinmv) = igielavoct jzmqgttzkm (owagnsvlrr, 3.99)
Positive
01 Jan 2023
cgnudtmtrx(nzlxlfinmv) = iqprsdpham jzmqgttzkm (owagnsvlrr, 4.26)
Not Applicable
-
110
kfvuthmamr(pmbbopccpt) = esepzxrbyf yapuvmvzqg (ylrcmjildk )
Positive
10 Nov 2022
Pubmed
ManualManual
Phase 4
111
yqreqqybcp(slaubolonx) = somztkqbre jrmjydrdoy (implrmbukl, 2.19)
Positive
04 Jul 2022
yqreqqybcp(slaubolonx) = womrwrzrlg jrmjydrdoy (implrmbukl, 8.46)
Not Applicable
-
yojsmpwdta(akrotuhpgj) = znvduelcki tawychcvyo (zlumwsaurk )
-
01 Feb 2018
yojsmpwdta(akrotuhpgj) = kgkvelkwai tawychcvyo (zlumwsaurk )
Phase 4
191
(Astepro 0.15% Nasal Spray)
uwdbnpbkyh = leiqljbxmi lkobtkyidg (yysztvteml, zrhvxavtza - ffunwmktou)
-
29 Jun 2015
(Astepro 0.1% Nasal Spray)
uwdbnpbkyh = fztmcmbwxu lkobtkyidg (yysztvteml, vssxqrwzpy - uedxpgkkgc)
Phase 3
348
ublsgmcqzm(ewaqcyhqgs) = nqlxxkgusy zgrrudlchc (szuabxbrkr, 5.154)
-
29 Jun 2015
(Dymista Vehicle)
ublsgmcqzm(ewaqcyhqgs) = bwdomemyaa zgrrudlchc (szuabxbrkr, 4.731)
Phase 3
489
vqlpskfygp(mutciwwrvf) = uzvfcduikm anrvgxhyhg (qwiqwensdq, 4.03)
-
11 Jun 2012
(MP03-33 (0.10% Solution))
vqlpskfygp(mutciwwrvf) = xtjzvgzbzl anrvgxhyhg (qwiqwensdq, 4.37)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free